Try our Advanced Search for more refined results
Life Sciences
Life Sciences Law360 provides breaking legal news and analysis on the pharmaceutical and medical device industry. Coverage includes high-stakes litigation and policy developments that affect life sciences companies, as well as licensing deals, mergers, and other corporate transactions.
Sign up for a 7-day FREE trial today!
Latest News in Life Sciences
-
February 18, 2026
FDA Changes Mind, Will Review Moderna MRNA Flu Vaccine
Moderna on Wednesday said that the U.S. Food and Drug Administration has decided to review its application for its influenza vaccine, a week after the agency refused to consider the application for the new experimental vaccine.
-
February 18, 2026
Federal Preemption In AI And Robotics Is Essential
Federal preemption offers a unified front at a decisive moment that is essential for safeguarding America's economic edge in artificial intelligence and robotics against global rivals, harnessing trillions of dollars in potential, securing high-skilled jobs through human augmentation, and defending technological sovereignty, says Steven Weisburd at Shook Hardy.
-
February 18, 2026
Levi & Korsinsky To Lead Novo Nordisk Investor Class Action
Levi & Korsinsky LLP has been appointed lead counsel in a proposed securities class action accusing Novo Nordisk A/S of misleading investors about its 2025 revenue outlook, after a New Jersey federal magistrate judge approved the firm's selection by the investor with the largest financial stake in the case.
-
February 18, 2026
Paul Hastings Adds Cooley Atty As Life Science Deals Leader
Paul Hastings LLP announced Wednesday that it has tapped a former Cooley LLP partner and one-time Merck & Co. attorney to chair its life sciences transactions team.
-
February 17, 2026
Judge Trims Moderna's Defenses In COVID Patent Suit
A federal judge sitting in Delaware on Tuesday ruled that Moderna could not use obviousness to defend itself from patent claims brought by a rival vaccine developer since it already used that as a defense in related Patent Trial and Review Board proceedings, saying that Moderna had offered expert opinions to support a defense that the patents don't sufficiently teach about the claimed invention.
Areas of Coverage
- AGENCIES
- U.S. Consumer Product Safety Commission
- U.S. Food and Drug Administration
- U.S. Patent and Trademark Office
- U.S. International Trade Commission
- POLICY & REGULATION
- Affordable Care Act
- Federal Food, Drug, and Cosmetic Act
- Antitrust and consumer protection controls
- Drug and medical device lobbying
- State and international life sciences legislation and regulation
- ENFORCEMENT
- Drug and medical device recalls
- Drug safety actions
- Pay-for-delay investigations
- Merger reviews
- LITIGATION
- Patent disputes, including
- Abbreviated New Drug Application litigation
- Section 301 cases
- Product safety suits over drugs and medical devices, including off-label marketing and failure-to-warn claims
- Consumer litigation and class actions
- Fraud and compliance suits
- Antitrust disputes
- Labor and employment suits
- Shareholder and corporate governance disputes
- Bankruptcy proceedings
- TRANSACTIONS
- Mergers, acquisitions, and joint ventures
- Share buybacks and stock splits
- Private equity deals
- Patent-licensing agreements
- PROFILES
- Personnel moves
- Profiles of life sciences practice groups
Readership
- Life sciences lawyers at top law firms
- Corporate counsel and compliance officers at Fortune 1000 companies
- Executives and attorneys in the drug, biotechnology, and medical device industries
- Information experts at law firms, agencies, and companies
- Policymakers at federal and state agencies
- Judges and court staff across the U.S.
- Professors, students, and library staff at every accredited law school in the U.S.
- Attorney and law firm marketing professionals